The Medicare GLP-1 Bridge: Access, Affordability & the Pharmacist’s Role | TWIRx
- 38m
- Transcript
Summary
Written by a model from the transcript; not yet reviewed.
This episode covers major pharmacy news and features an interview with Dr. Javi Hamilton, Senior Pharmacy Director at Buzz Health, discussing medication access and the Medicare GLP-1 bridge program. The host explores pressing industry topics including a federal audit on Medicare Part D overpayments for over-the-counter drugs, supply pressures on estradiol patches, conflicting pediatric and obstetric vaccine guidelines, and a proposed CMS rule that would exclude contracted pharmacists from billing remote patient monitoring services. Dr. Hamilton breaks down how the new Medicare GLP-1 bridge program operates outside traditional Part D coverage, offering long-term weight management medications at a fixed fifty-dollar monthly copay while highlighting crucial considerations around deductibles, sustainability, and employer-sponsored retiree plans.
Listeners get a detailed look at non-traditional career paths for pharmacists and practical strategies for navigating complex policy changes and patient counseling barriers. The discussion provides clear insights into how healthcare policies impact daily pharmacy operations and why pharmacist advocacy and patient education remain essential.
- Medicare Part D plans made nearly 588 million dollars in improper payments between 2021 and 2023 for medications transitioning from prescription to over-the-counter status. 4:40
- The Medicare GLP-1 bridge program operates outside traditional Part D coverage with its own prior authorization and payment systems, offering eligible beneficiaries long-term weight management medication for fifty dollars per month. 23:42
- Copayments made under the Medicare GLP-1 bridge program do not count toward a patient's Part D deductible or out-of-pocket maximum. 24:58
- Under a proposed CMS rule for the 2027 physician fee schedule, remote patient monitoring and remote treatment management services delivered by contractors would no longer be billable. 11:19
Highlights
- 4:40
Medicare Over-The-Counter Drug Paymentsdata
An HHS OIG audit reveals hundreds of millions in improper Part D payments for drugs that switched to over-the-counter status, highlighting coordination gaps between the FDA, CMS, and plan sponsors.
- 5:51
Estradiol Patch Supply Pressuresinsight
The FDA is working with six manufacturers to increase production of transdermal patches amid rising demand, leaving pharmacists on the front lines to manage frustrated patients and communicate with prescribers.
- 6:55
Conflicting Respiratory Vaccine Guidelinesinsight
New RSV and COVID recommendations from professional societies create clinical confusion for pharmacists who must navigate unsettled federal guidance while counseling patients.
- 11:19
Proposed CMS Rule Threatens RPMstrategy
A proposed change in the 2027 Medicare physician fee schedule would restrict remote patient monitoring and treatment management billing exclusively to clinical staff employed directly by the practice, excluding contractors.
- 20:06
Transitioning to Industry Leadershipstory
Dr. Javi Hamilton shares her career journey from clinical hospital pharmacy and burnout during COVID to becoming Senior Pharmacy Director at Buzz Health, focusing on health equity and medication access.
- 23:42
Structure of the GLP-1 Bridgeinsight
The Medicare bridge program provides long-term weight management GLP-1 medications at a fixed fifty-dollar monthly copayment, running separately from standard Part D benefits until December 2027.
- 26:51
Employer Group Waiver Plan Confusioninsight
Retirees covered under employer-sponsored Part D plans often remain unaware of whether they qualify for specialized bridge programs, creating an educational opening for pharmacists and benefit managers.
About this episode
TWIRx NEWS 1. Medicare Part D Paid Nearly $588 Million for Ineligible OTC Drugs A federal audit found that Medicare Part D sponsors made approximately $587.7 million in ineligible payments from 2021 through 2023 for medications that had effectively transitioned from prescription to over-the-counter status. The HHS Office of Inspector General cited outdated FDA information and the lack of a clear CMS rejection timeline as major contributors. Why it matters: This exposes a serious coordination problem across FDA data, manufacturers, CMS, health plans and pharmacy claims systems. Pharmacists may see the rejection or payment issue at the counter, but the failure often begins far upstream. Read the Fierce Healthcare reportRead the HHS-OIG audit 2. FDA Responds to Estradiol Patch Supply Pressure The FDA is working with six manufacturers to improve access to estradiol transdermal patches amid increased demand. While FDA has not declared a national shortage, availability varies by product, strength and geographic area. Manufacturers are increasing production through larger batches, added shifts and expanded capacity. Why it matters: Pharmacists are again serving as the front line of a supply-chain challenge—helping patients locate medication, coordinating with prescribers and identifying alternatives. Read the Reuters reportRead the FDA update 3. New RSV and COVID-19 Guidance Released The American Academy of Pediatrics and American College of Obstetricians and Gynecologists have issued updated recommendations for RSV and COVID-19 protection during the 2026–2027 respiratory season. Why it matters: Pharmacists may face conflicting recommendations, patient confusion and questions about eligibility. Clear counseling and coordination with pediatric and obstetric providers will be critical. Read the Pharmacy Times report SPECIAL ANNOUNCEMENT FROM OUTCOMES A special update from Megan Urban and Outcomes. Outcomes is highlighting new enhancements to its Rx30 pharmacy management platform, including a refreshed user experience, automated data-entry capabilities and support from a dedicated Client Success Team. The program will explore how these updates can streamline pharmacy workflows, save time and support greater focus on patient care. Presented by: Dalia Rios and Kaley LesterSeptember 9, 2026 — 1:30 p.m. ET Register here FEATURED CONVERSATION Building a Bridge to GLP-1 Access Our featured guest is HaVy Ngo-Hamilton, PharmD, RPh, Senior Pharmacy Director at Buzz Health. HaVy works at the intersection of pharmacy, healthcare technology, medication affordability and prescription access. Buzz Health operates platforms including BuzzRx, RxCompare and RxAffect, with a focus on helping connect patients, pharmacies, prescribers and prescription pricing information. That makes today’s discussion particularly timely. THE MEDICARE GLP-1 BRIDGE CMS launched the Medicare GLP-1 Bridge on July 1, 2026, to provide eligible Medicare Part D beneficiaries access to selected GLP-1 medications for weight management. The demonstration runs through December 31, 2027. Eligible beneficiaries pay $50 for a monthly supply, while the program operates outside the traditional Part D payment flow through centralized prior authorization, claims adjudication and pharmacy payment. Eligible therapies currently include: Foundayo®Wegovy®Zepbound® The bigger issue is not simply GLP-1 coverage. It is how healthcare connects eligibility, affordability, prior authorization, pharmacy workflow and patient access. The central question for today’s discussion: Can we create a medication-access system where patients know whether they can obtain and afford their therapy before they reach the pharmacy counter? CLOSING THOUGHT The Medicare GLP-1 Bridge is more than another federal drug program. It is a real-world test of how healthcare can better connect coverage, affordability, prior authorization and pharm
Transcript
5,454 words · 6 speakers
Topics
- Medicare Part D
- GLP-1 Access
- Pharmacy Practice
- Remote Patient Monitoring
- Drug Supply Chain
- Healthcare Policy
- Pharmacist Career
Page updated · transcript and summary are machine-generated